Characterization of a cohort of metastatic lung cancer patients harboring KRAS mutations treated with immunotherapy

Notario Rincón, Lucía; Cucurull, Marc|||0000-0003-2588-567X; Cerdà, Gabriela; Sanz, Carolina; Carcereny, Enric|||0000-0001-5235-5602; Muñoz-Mármol, Ana; Hernández, Ainhoa|||0000-0003-4678-6662; Domènech, Marta|||0000-0003-4827-9170; Morán, Teresa; Sánchez Céspedes, Montse|||0000-0002-6045-5627; Costa, Marta; Mate, Jose Luis; Esteve, Anna|||0000-0002-1962-971X; Saigí, Maria|||0000-0001-5815-5388

Characterization of a cohort of metastatic lung cancer patients harboring KRAS mutations treated with immunotherapy

Approximately 20% of lung adenocarcinomas harbor activating mutations at KRAS, an oncogene with the ability to alter the tumor immune microenvironment. In this retrospective study, we examined 103 patients with KRAS-mutant lung adenocarcinoma who were treated with immunotherapy-based regimens and we...

Descripción completa

Detalles Bibliográficos
Autores:	Notario Rincón, Lucía, Cucurull, Marc\|\|\|0000-0003-2588-567X, Cerdà, Gabriela, Sanz, Carolina, Carcereny, Enric\|\|\|0000-0001-5235-5602, Muñoz-Mármol, Ana, Hernández, Ainhoa\|\|\|0000-0003-4678-6662, Domènech, Marta\|\|\|0000-0003-4827-9170, Morán, Teresa, Sánchez Céspedes, Montse\|\|\|0000-0002-6045-5627, Costa, Marta, Mate, Jose Luis, Esteve, Anna\|\|\|0000-0002-1962-971X, Saigí, Maria\|\|\|0000-0001-5815-5388
Tipo de recurso:	artículo
Fecha de publicación:	2023
País:	España
Institución:	Universitat Autònoma de Barcelona
Repositorio:	Dipòsit Digital de Documents de la UAB
Idioma:	inglés
OAI Identifier:	oai:ddd.uab.cat:289738
Acceso en línea:	https://ddd.uab.cat/record/289738 https://dx.doi.org/urn:doi:10.3389/fonc.2023.1239000
Access Level:	acceso abierto
Palabra clave:	Non-small cell lung cancer Lung adenocarcinoma KRAS PD-L1 Immunotherapy

id	ES_92e1a16cb6be7a67237c0af0155aec7e
oai_identifier_str	oai:ddd.uab.cat:289738
network_acronym_str	ES
network_name_str	España
repository_id_str
spelling	Characterization of a cohort of metastatic lung cancer patients harboring KRAS mutations treated with immunotherapydifferences according to KRAS G12C vs. non-G12CNotario Rincón, LucíaCucurull, Marc\|\|\|0000-0003-2588-567XCerdà, GabrielaSanz, CarolinaCarcereny, Enric\|\|\|0000-0001-5235-5602Muñoz-Mármol, AnaHernández, Ainhoa\|\|\|0000-0003-4678-6662Domènech, Marta\|\|\|0000-0003-4827-9170Morán, TeresaSánchez Céspedes, Montse\|\|\|0000-0002-6045-5627Costa, MartaMate, Jose LuisEsteve, Anna\|\|\|0000-0002-1962-971XSaigí, Maria\|\|\|0000-0001-5815-5388Non-small cell lung cancerLung adenocarcinomaKRASPD-L1ImmunotherapyApproximately 20% of lung adenocarcinomas harbor activating mutations at KRAS, an oncogene with the ability to alter the tumor immune microenvironment. In this retrospective study, we examined 103 patients with KRAS-mutant lung adenocarcinoma who were treated with immunotherapy-based regimens and we evaluated the clinical outcomes according to PD-L1 expression and the type of KRAS mutation. Among all patients included, 47% carried KRAS G12C mutation whereas 53% harbored KRAS non-G12C mutations. PD-L1 status was available for 77% of cases, with higher expression among KRAS G12C tumors (p = 0.01). Better overall survival and progression-free survival were observed in high PD-L1 expression tumors, regardless of KRAS mutation type. The heterogeneous nature of KRAS-mutant tumors and the presence of other co-mutations may contribute to different outcomes to immunotherapy-based strategies. 22023-01-0120232023-01-01Articlehttp://purl.org/coar/resource_type/c_6501VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://ddd.uab.cat/record/289738https://dx.doi.org/urn:doi:10.3389/fonc.2023.1239000reponame:Dipòsit Digital de Documents de la UABinstname:Universitat Autònoma de BarcelonaInglésengInstituto de Salud Carlos III https://doi.org/10.13039/501100004587 CM19/0068Instituto de Salud Carlos III https://doi.org/10.13039/501100004587 JR20/00015open accesshttp://purl.org/coar/access_right/c_abf2Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.https://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:ddd.uab.cat:2897382026-06-06T12:50:31Z
dc.title.none.fl_str_mv	Characterization of a cohort of metastatic lung cancer patients harboring KRAS mutations treated with immunotherapy differences according to KRAS G12C vs. non-G12C
title	Characterization of a cohort of metastatic lung cancer patients harboring KRAS mutations treated with immunotherapy
spellingShingle	Characterization of a cohort of metastatic lung cancer patients harboring KRAS mutations treated with immunotherapy Notario Rincón, Lucía Non-small cell lung cancer Lung adenocarcinoma KRAS PD-L1 Immunotherapy
title_short	Characterization of a cohort of metastatic lung cancer patients harboring KRAS mutations treated with immunotherapy
title_full	Characterization of a cohort of metastatic lung cancer patients harboring KRAS mutations treated with immunotherapy
title_fullStr	Characterization of a cohort of metastatic lung cancer patients harboring KRAS mutations treated with immunotherapy
title_full_unstemmed	Characterization of a cohort of metastatic lung cancer patients harboring KRAS mutations treated with immunotherapy
title_sort	Characterization of a cohort of metastatic lung cancer patients harboring KRAS mutations treated with immunotherapy
dc.creator.none.fl_str_mv	Notario Rincón, Lucía Cucurull, Marc\|\|\|0000-0003-2588-567X Cerdà, Gabriela Sanz, Carolina Carcereny, Enric\|\|\|0000-0001-5235-5602 Muñoz-Mármol, Ana Hernández, Ainhoa\|\|\|0000-0003-4678-6662 Domènech, Marta\|\|\|0000-0003-4827-9170 Morán, Teresa Sánchez Céspedes, Montse\|\|\|0000-0002-6045-5627 Costa, Marta Mate, Jose Luis Esteve, Anna\|\|\|0000-0002-1962-971X Saigí, Maria\|\|\|0000-0001-5815-5388
author	Notario Rincón, Lucía
author_facet	Notario Rincón, Lucía Cucurull, Marc\|\|\|0000-0003-2588-567X Cerdà, Gabriela Sanz, Carolina Carcereny, Enric\|\|\|0000-0001-5235-5602 Muñoz-Mármol, Ana Hernández, Ainhoa\|\|\|0000-0003-4678-6662 Domènech, Marta\|\|\|0000-0003-4827-9170 Morán, Teresa Sánchez Céspedes, Montse\|\|\|0000-0002-6045-5627 Costa, Marta Mate, Jose Luis Esteve, Anna\|\|\|0000-0002-1962-971X Saigí, Maria\|\|\|0000-0001-5815-5388
author_role	author
author2	Cucurull, Marc\|\|\|0000-0003-2588-567X Cerdà, Gabriela Sanz, Carolina Carcereny, Enric\|\|\|0000-0001-5235-5602 Muñoz-Mármol, Ana Hernández, Ainhoa\|\|\|0000-0003-4678-6662 Domènech, Marta\|\|\|0000-0003-4827-9170 Morán, Teresa Sánchez Céspedes, Montse\|\|\|0000-0002-6045-5627 Costa, Marta Mate, Jose Luis Esteve, Anna\|\|\|0000-0002-1962-971X Saigí, Maria\|\|\|0000-0001-5815-5388
author2_role	author author author author author author author author author author author author author
dc.subject.none.fl_str_mv	Non-small cell lung cancer Lung adenocarcinoma KRAS PD-L1 Immunotherapy
topic	Non-small cell lung cancer Lung adenocarcinoma KRAS PD-L1 Immunotherapy
description	Approximately 20% of lung adenocarcinomas harbor activating mutations at KRAS, an oncogene with the ability to alter the tumor immune microenvironment. In this retrospective study, we examined 103 patients with KRAS-mutant lung adenocarcinoma who were treated with immunotherapy-based regimens and we evaluated the clinical outcomes according to PD-L1 expression and the type of KRAS mutation. Among all patients included, 47% carried KRAS G12C mutation whereas 53% harbored KRAS non-G12C mutations. PD-L1 status was available for 77% of cases, with higher expression among KRAS G12C tumors (p = 0.01). Better overall survival and progression-free survival were observed in high PD-L1 expression tumors, regardless of KRAS mutation type. The heterogeneous nature of KRAS-mutant tumors and the presence of other co-mutations may contribute to different outcomes to immunotherapy-based strategies.
publishDate	2023
dc.date.none.fl_str_mv	2 2023-01-01 2023 2023-01-01
dc.type.none.fl_str_mv	Article http://purl.org/coar/resource_type/c_6501 VoR http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv	info:eu-repo/semantics/article
format	article
dc.identifier.none.fl_str_mv	https://ddd.uab.cat/record/289738 https://dx.doi.org/urn:doi:10.3389/fonc.2023.1239000
url	https://ddd.uab.cat/record/289738 https://dx.doi.org/urn:doi:10.3389/fonc.2023.1239000
dc.language.none.fl_str_mv	Inglés eng
language_invalid_str_mv	Inglés
language	eng
dc.relation.none.fl_str_mv	Instituto de Salud Carlos III https://doi.org/10.13039/501100004587 CM19/0068 Instituto de Salud Carlos III https://doi.org/10.13039/501100004587 JR20/00015
dc.rights.none.fl_str_mv	open access http://purl.org/coar/access_right/c_abf2 https://creativecommons.org/licenses/by/4.0/
dc.rights.openaire.fl_str_mv	info:eu-repo/semantics/openAccess
rights_invalid_str_mv	open access http://purl.org/coar/access_right/c_abf2 https://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv	openAccess
dc.format.none.fl_str_mv	application/pdf
dc.source.none.fl_str_mv	reponame:Dipòsit Digital de Documents de la UAB instname:Universitat Autònoma de Barcelona
instname_str	Universitat Autònoma de Barcelona
reponame_str	Dipòsit Digital de Documents de la UAB
collection	Dipòsit Digital de Documents de la UAB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_	1869413521486249984
score	15,301629

Characterization of a cohort of metastatic lung cancer patients harboring KRAS mutations treated with immunotherapy

Similares en LA Referencia